Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Drops By 69.4%

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 5,029,282 shares, a decrease of 69.4% from the November 30th total of 16,419,579 shares. Approximately 12.3% of the shares of the company are short sold. Based on an average daily trading volume, of 8,567,200 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 8,567,200 shares, the short-interest ratio is presently 0.6 days. Approximately 12.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Voleon Capital Management LP bought a new stake in Capricor Therapeutics in the 3rd quarter valued at $311,000. Moneta Group Investment Advisors LLC boosted its position in shares of Capricor Therapeutics by 25.5% during the 3rd quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 7,000 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Capricor Therapeutics in the third quarter valued at about $123,000. Raymond James Financial Inc. raised its position in Capricor Therapeutics by 1,629.9% in the third quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock worth $1,379,000 after purchasing an additional 180,234 shares in the last quarter. Finally, Brooklyn Investment Group bought a new position in Capricor Therapeutics during the third quarter worth about $274,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $29.29 on Friday. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The stock has a market cap of $1.34 billion, a PE ratio of -16.27 and a beta of 0.61. The firm has a 50-day simple moving average of $13.31 and a 200 day simple moving average of $9.87.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). Research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CAPR shares. HC Wainwright boosted their target price on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Maxim Group lifted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Industrial Alliance Securities set a $48.00 target price on Capricor Therapeutics in a research note on Wednesday, December 3rd. Roth Capital raised their target price on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Oppenheimer lifted their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.82.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.